Adolore Biotherapeutics develops a locally-administered, disease-modifying gene therapy that delivers a proprietary analgesic peptide directly into pain-sensing nerve fibers to treat chronic pain without the use of opioids. This approach addresses the urgent need for safe and effective non-opioid therapies in the context of the opioid crisis, particularly for conditions like chronic osteoarthritis knee pain.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic pain conditions, such as osteoarthritis and erythromelalgia, often lack effective long-term treatments, leading to reliance on opioid-based medications with significant side effects and addiction potential. Current pain management strategies frequently fail to address the underlying causes of pain, providing only symptomatic relief. The need for non-opioid, disease-modifying therapies that can provide lasting pain relief without systemic side effects remains a significant unmet need.
Solution
Adolore BioTherapeutics is developing locally-administered gene therapies designed to provide long-lasting, non-opioid pain relief. Their approach involves delivering a proprietary analgesic peptide directly to pain-sensing nerve fibers via a non-replicating viral vector. This targeted delivery aims to modify the disease and alleviate pain at its source, minimizing systemic exposure and potential side effects. The lead program focuses on chronic osteoarthritis knee pain, with additional programs targeting erythromelalgia and other chronic pain conditions.
Target Audience
The primary target audience includes individuals suffering from chronic pain conditions, such as chronic osteoarthritis knee pain and erythromelalgia, as well as physicians and specialists seeking non-opioid alternatives for pain management.
Features
- Locally-administered gene therapy for targeted delivery of analgesics
- Non-replicating viral vector for enhanced safety profile
- Proprietary CA8 analgesic peptide designed to act within sensory neurons
- Disease-modifying approach to address the underlying causes of chronic pain
- Pipeline includes ADB-101 for chronic osteoarthritis knee pain and ADB-102 for erythromelalgia